Biotech | September 08, 2021
Biocon settles suit with Celgene for generic Revlimid
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
The company said Revital NXT is India’s first nutrition bar with the goodness of natural ginseng, 16 vitamins & minerals and triple blend protein
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
First launched in 2005, pharmaREADY is a fully integrated, regulatory compliant, web-based platform to create, view, and manage global regulatory submissions
The lab will offer over 4,000 clinical tests and profiles and can conduct over 20,000 sample tests per month.
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
In comparison to traditional open-heart surgery, which involves opening up the chest by splitting the breastbone, da Vinci Xi's innovative technology allows for complex cardiovascular surgeries to be performed through smaller incisions and precise motion control
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
Subscribe To Our Newsletter & Stay Updated
